It is also essential to determine whether pathogenic mechanisms associated with LRRK2-PD may be present at the prodromal stage in non-manifesting LRRK2 mutation carriers and in a subset of idiopathic PD. This evidence concerns the gene LRRK2 and Parkinson disease.